15Nov 2024
Study Reveals Pristimerin’s Potential as Anti-Arthritic Agent in Rheumatoid Arthritis

Study Reveals Pristimerin’s Potential as Anti-Arthritic Agent in Rheumatoid Arthritis

In a preclinical study, pristimerin, a natural triterpenoid, showed promising anti-arthritic effects in a collagen antibody-induced arthritis (CAIA) mouse model of rheumatoid arthritis (RA). Over a 9-day treatment period, pristimerin effectively reduced arthritis severity, with micro-CT and histology confirming improvements in joint health. Mechanistic analysis revealed pristimerin’s action on pro-inflammatory cytokines, chemokines, and key mediators of angiogenesis and bone remodeling, including the Notch signaling pathway. This is the first report linking pristimerin to the Notch pathway in arthritis, supporting its potential as a novel therapeutic option for RA patients unresponsive to existing treatments.

  • #rheumatology

Like

Save

Share